Sanofi's 'daughter of Dupixent' heads to phase 3 in asthma

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a midstage trial.